BMJ Open
August 2020
Objectives: We aimed to calculate cumulative hepatitis C virus (HCV) treatment coverage among individuals enrolled in opioid agonist therapy (OAT) in Norway between 2013 and 2017 and to document the treatment transition to direct-acting antiviral (DAA) agents. Moreover, we aimed to describe adherence to DAAs in the same cohort.
Design: Prospective cohort, registry data.
Tidsskr Nor Laegeforen
September 2016